Longeveron LLC

General Information

We are a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. Our lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders.

We are currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Our mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.

Industry: Pharmaceuticals
Employees: 16
Founded: 2014
Contact Information
Address 1951 NW 7th Avenue, Suite 520 Miami, Florida 33136
Phone Number (305) 909-0840
Web Address http://www.longeveron.com
View Prospectus: Longeveron LLC
Financial Information
Market Cap $187mil
Revenues $6.29 mil (last 12 months)
Net Income $-2.8 mil (last 12 months)
IPO Profile
Symbol LGVN
Exchange NASDAQ
Shares (millions): 2.7
Price range $10.00 - $10.00
Est. $ Volume $26.6 mil
Manager / Joint Managers EF Hutton
CO-Managers Alexander Capital
Expected To Trade: 2/12/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change